Lymphogranuloma venereum future or investigational therapies: Difference between revisions

	Lymphogranuloma venereum Microchapters
Home
Patient Information
Overview
Historical Perspective
Pathophysiology
Causes
Classification
Differentiating Lymphogranuloma venereum from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Lymphogranuloma venereum future or investigational therapies On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Lymphogranuloma venereum future or investigational therapies All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Lymphogranuloma venereum future or investigational therapies
CDC on Lymphogranuloma venereum future or investigational therapies
Lymphogranuloma venereum future or investigational therapies in the news
Blogs on Lymphogranuloma venereum future or investigational therapies
Directions to Hospitals Treating Lymphogranuloma venereum
Risk calculators and risk factors for Lymphogranuloma venereum future or investigational therapies

Revision as of 15:17, 11 December 2012

Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.

@@ Line 1: / Line 1: @@
 __NOTOC__
 {{Lymphogranuloma venereum}}
-{{CMG}}
-==Overview==
+Please help WikiDoc by adding content here. It's easy! Click [[Help:How_to_Edit_a_Page|here]] to learn about editing.
-==Future or Investigational Therapies==
-As with all [[Sexually transmitted disease|STD]]'s sex partners of patients who have LGV should be examined and tested for [[urethra]]l or [[cervix|cervical]] [[chlamydia]]l infection. After a positive culture for chlamydia, clinical suspicion should be confirmed with  testing to distinguish serotype.  Antibiotic treatment should be started if they had sexual contact with the patient during the 30 days preceding onset of symptoms in the patient. Patients with a sexually transmitted disease need to be tested for other STD's.  Antibiotics are not without risks and prophylaxtic broad antibiotic coverage is not recommended.
 ==References==
 {{reflist|2}}
 [[Category:Sexually transmitted diseases]]
-[[Category:Needs overview]]
+[[Category:Needs content]]
 [[Category:Disease]]
 [[Category:Gynecology]]